PA Ganz
About
PA Ganz is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, PA Ganz has authored 26 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in PA Ganz's work include Breast Cancer Treatment Studies (12 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (4 papers). PA Ganz is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (4 papers). PA Ganz collaborates with scholars based in United States, Canada and Australia. PA Ganz's co-authors include John Adams, Mark Pearson, Katherine L. Kahn, Virginia Erickson, Pamela J. Goodwin, Louise Bordeleau, Kimberly A. McGuigan, Christiane Bréant, Carol M. Moinpour and Scott M. Lippman and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.
In The Last Decade
PA Ganz
26 papers receiving 807 citations
Peers
PA Ganz
Seraina Schmid Switzerland
Jung-Hyun Yang South Korea
D.B.Y. Fontein Netherlands
Ilonka Evans United States
Weijiang Liang China
Young Up Cho South Korea
C. Seynaeve Netherlands
Jeremy S. H. Jackson Canada
Amanda L. Kong United States
Katia Cannita Italy
Citations per year, relative to PA Ganz PA Ganz (= 1×)
peers
Seraina Schmid
Countries citing papers authored by PA Ganz
Since
Specialization
Citations
This map shows the geographic impact of PA Ganz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PA Ganz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PA Ganz more than expected).
Fields of papers citing papers by PA Ganz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by PA Ganz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PA Ganz. The network helps show where PA Ganz may publish in the future.
Co-authorship network of co-authors of PA Ganz
This figure shows the co-authorship network connecting the top 25 collaborators of PA Ganz. A scholar is included among the top collaborators of PA Ganz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PA Ganz. PA Ganz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pusztai, Lajos, PA Ganz, N. Lynn Henry, et al.. (2018). Abstract OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. Cancer Research. 78(4_Supplement). OT1–2.
2.
Chávez‐MacGregor, Mariana, Lajos Pusztai, Priya Rastogi, et al.. (2016). Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). Cancer Research. 76(4_Supplement). OT1–3.
3.
Ganz, PA, TB Julian, J. P. Costantino, et al.. (2016). Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Cancer Research. 76(4_Supplement). S6–4.
4.
Mamounas, EP, Hanna Bandos, TB Julian, et al.. (2016). Abstract OT2-02-02: NRG Oncology/NSABP B-51/RTOG 1304: A phase III clinical trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC). Cancer Research. 76(4_Supplement). OT2–2.
5.
Rastogi, Priya, EP Mamounas, PA Ganz, et al.. (2012). Abstract OT2-2-04: A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/− one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NSABP S1207.. Cancer Research. 72(24_Supplement). OT2–2.
6.
Domchek, S. M., Tara M. Friebel, Susan L. Neuhausen, et al.. (2011). Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?. Journal of Clinical Oncology. 29(15_suppl). 1501–1501.
7.
Cescon, David W., Marguerite Ennis, PA Ganz, et al.. (2011). An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs).. Journal of Clinical Oncology. 29(15_suppl). 596–596.
8.
Fehrenbacher, L., Priya Rastogi, CE Geyer, et al.. (2011). OT1-02-07: NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2−Low Invasive Breast Cancer.. Cancer Research. 71(24_Supplement). OT1–2.
9.
Ganz, PA, et al.. (2010). Abstract P5-13-09: Feasibility of a Randomized Controlled Trial of Vitamin D vs. Placebo in Recently Diagnosed Breast Cancer Patients. Cancer Research. 70(24_Supplement). P5–13.
10.
Swain, SM, Joon Jeong, CE Geyer, et al.. (2009). NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Cancer Research. 69(2_Supplement). 75–75.
11.
Kopec, Jacek A., Sarah R. Haile, Mathilde Ritter, et al.. (2008). Quality of life in breast cancer patients receiving sentinel-node (SN) biopsy alone or with axillary dissection (AD): Results from NSABP Protocol B-32. Journal of Clinical Oncology. 26(15_suppl). 9533–9533.
12.
Moinpour, Carol M., Amy K. Darke, Gary Donaldson, et al.. (2007). Longitudinal Analysis of Sexual Function Reported by Men in the Prostate Cancer Prevention Trial. JNCI Journal of the National Cancer Institute. 99(13). 1025–1035.
13.
Geyer, CE, E. Mamounas, Lawrence Wickerham, et al.. (2007). P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33. The Breast. 16. S46–S46.
14.
Goodwin, Pamela J., et al.. (2003). Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer--Taking Stock. JNCI Journal of the National Cancer Institute. 95(4). 263–281.
15.
Erickson, Virginia, Mark Pearson, PA Ganz, John Adams, & Katherine L. Kahn. (2001). Arm Edema in Breast Cancer Patients. JNCI Journal of the National Cancer Institute. 93(2). 96–111.
16.
Castellon, S. A., et al.. (2001). Neurocognitive performance in breast cancer following exposure to adjuvant systemic therapy. Archives of Clinical Neuropsychology. 16(8). 859–860.
17.
Ganz, PA, John Rowland, Beth E. Meyerowitz, & Karen Desmond. (1998). S39 Impact of different adjuvant therapy strategies on quality of life (QOL) in breast cancer survivors (BCS). European Journal of Cancer. 34. S9–S10.
18.
McGuigan, Kimberly A., PA Ganz, & Christiane Bréant. (1996). Agreement Between Breast Cancer Risk Estimation Methods. JNCI Journal of the National Cancer Institute. 88(18). 1315–1317.
19.
Ganz, PA. (1994). Breast Cancer in Older Women: Quality-of-Life Considerations.. PubMed. 1(4). 372–379.
20.
Ganz, PA, et al.. (1993). Nutrition and breast cancer.. PubMed. 7(12). 71–5; discussion 76, 79.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Seraina Schmid Breakdown of academic impact, for papers by Jung-Hyun Yang Breakdown of academic impact, for papers by D.B.Y. Fontein Breakdown of academic impact, for papers by Ilonka Evans Breakdown of academic impact, for papers by Weijiang Liang Breakdown of academic impact, for papers by Young Up Cho Breakdown of academic impact, for papers by C. Seynaeve Breakdown of academic impact, for papers by Jeremy S. H. Jackson Breakdown of academic impact, for papers by Amanda L. Kong Breakdown of academic impact, for papers by Katia Cannita